Status
Conditions
Treatments
Study type
Funder types
Identifiers
About
We will test the hypothesis that increasing skin wetness, and thus evaporative cooling, will attenuate the increase in core body temperature and accompanying cardiac stress during heat wave conditions in individuals with congestive heart failure. Secondly, we propose that fan use alone may be possibly detrimental (very hot and dry) depending on the environmental conditions. To accomplish these objectives, individuals with congestive heart failure and otherwise healthy control individuals will be exposed to the simulated heat wave condition (very hot and dry) with the following cooling modalities: A) control trial (no fan or skin wetting), B) skin wetting only trial, and C) fan only trial in a randomized crossover fashion. Thermoregulatory and cardiovascular responses will be evaluated throughout these simulated heat wave exposures.
Primary outcomes variables will be skin and core temperatures, while secondary variables will include measures of cardiovascular stress, myocardial perfusion, heart rate, and echo-based measures of cardiac function.
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Inclusion Criteria for healthy control participants:
Exclusion Criteria for healthy control participants:
Inclusion Criteria for Participants with CHF:
Exclusion Criteria for Participants with CHF:
-Patients who do not have confirmed diagnosis of NYHA class II or III heart failure will be excluded from the clinical group. Potential participants with cancer, diabetes, neurological disease, lung disease, and/or uncontrolled hypertension will be excluded. Potential participants with a left bundle branch block on ECG will be excluded, as well as those with an ejection fraction >40%. Patients on anticoagulant therapy will also be excluded. Participants with a body mass index ≥ 35 kg/m2 will be excluded. Current smokers, as well as individuals who regularly smoked within the past 9 months, will be excluded. Further exclusions will include severe valvular or congenital heart disease, acute myocarditis, NYHA Class IV heart failure, and/or manifest/provocable ischemic heart disease.
Primary purpose
Allocation
Interventional model
Masking
88 participants in 2 patient groups
Loading...
Central trial contact
Craig Crandall, PhD; Erin Harper, BS
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal